Cervical cancer is the second most common cancer among Indian women. According to the World Health Organisation, there are around 1.23 lakh new cases of cervical cancer annually in India and approximately 67,000 fatalities.
This translates into a fifth of the global burden of cervical cancer. The majority of cervical cancer cases are caused by different strains of the Human Papillomavirus (HPV), a sexually transmitted infection.
In a landmark achievement, India has announced the launch of its very first indigenously produced vaccine which is effective against strains 16 and 18 of HPV, the two types that account for 70 per cent of all cervical cancers worldwide.
The vaccine, Ceravac, will be rolled out by the Serum Institute of India and the Government’s Department of Biotechnology.
At just Rs. 200-400 per dose, Ceravac will be far more affordable than the current cervical cancer vaccines available in India. The existing vaccines, Gardasil and Cervarix, cost Rs. 3,927 and Rs. 2,640 for one vial respectively. The cervical cancer vaccine is administered in 2-3 doses several months apart to complete the dose regimen.
Ceravac, if rolled out at scale, can save the lives of a large number of girls and women and also preserve their quality of life.
It can also help India to reduce its burden of non-communicable diseases and achieve certain health related targets under the Sustainable Development Goals.
As per the World Health Organisation’s cervical cancer elimination strategy for 2030, 90 per cent of girls should be fully immunized with the HPV vaccine by the age of 15 years.
There are several channels through which Ceravac can be delivered. It can be integrated with the national immunization programme. India also has a school health programme which reaches out to large numbers of children and adolescents.
Further, the government has set up over 1.2 lakh Health and Wellness Centres (HWCs) across the country and the plan is to establish 1.5 lakh such Centres by end December, 2022. The vaccine can be integrated with the cervical cancer screening initiative being undertaken at the HWCs.
Eventually the vaccine can also be rolled out in partnership with the private sector. This will be an important step as a large part of the population seeks healthcare from private sector facilities.
India has a robust national immunization programme and several lessons can be leveraged from its roll out for the implementation of the cervical cancer vaccine too. Additionally, India has recently implemented a highly successful nationwide effort for the Covid vaccine and also developed the CoWin application for technology-based tracking.
It will be important to put in place a strong monitoring mechanism for tracking the delivery of the cervical vaccine as well to ensure that every individual receives the full dose regimen.
While the cervical cancer vaccine programme will be focused on girls, in due course, vaccination of boys could also be considered as they can be carriers of HPV. Further, HPV not only causes cervical cancer but is also responsible for certain other types like anal cancer.
Read More at https://swarajyamag.com/science/why-the-rollout-of-indias-first-indigenous-cervical-cancer-vaccine-is-a-landmark-achievement